Skip to content
OpenCapital
Get started

Intellia Therapeutics NTLA Cash & Equivalents

Cash & Equivalents at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$173.38M-34.4%
ALN
Alnylam PharmaceuticalsALNY
$1.71B+67.5%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
$423.31M+80.0%
Beam Therapeutics logo
Beam TherapeuticsBEAM
$288.29M-45.4%
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
$196.51M+14.5%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$176.35M+51.7%

Other financials

Income statement

See full
Revenue$15.0M-9.5%
Operating income-$100.5M+16.8%
Net income-$96.2M+15.8%
EPS (diluted)-$0.81+26.4%

Balance sheet

See full
Total debt$80.5M-32.5%
Total equity$620.9M-20.4%
Total assets$758.8M-23.1%

Cash flow

See full
Operating cash flow-$117.3M+21.2%
CapEx$79.0K-89.3%
Free cash flow-$117.4M+21.5%

Valuation

See full
Market cap$2.13B+106%
Enterprise value$2.08B+100%
P/S32.2×+9.5×

Profitability

See full
Operating margin-636.6%-202pp
Net margin-597%-194pp
FCF margin-550.2%-140pp

Returns & leverage

See full
Return on equity-56.3%-1.5pp
Debt / equity0.1×0.0×
Current ratio6.1×+1.2×

Where this comes from

Reported directly by Intellia Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: Intellia Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Intellia Therapeutics's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Intellia Therapeutics's cash & equivalents?
Intellia Therapeutics (NTLA) reported cash & equivalents of $134.7M in Q1 2026.
How has Intellia Therapeutics's cash & equivalents changed year-over-year?
Intellia Therapeutics's cash & equivalents increased by 6.2% year-over-year, from $126.88M to $134.7M.
What is the long-term trend for Intellia Therapeutics's cash & equivalents?
Over 5 years (2020 to 2025), Intellia Therapeutics's cash & equivalents has grown at a -0.6% compound annual growth rate (CAGR), from $160.02M to $155.46M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.